Julia Rotow MD @JuliaRotow

Medical Oncologist, Lowe Center for Thoracic Oncology @DanaFarber Instructor in Medicine, Harvard Medical School #NSCLC #EGFR Joined February 2016

Tweets

18
Followers

713
Following

32
Likes

9

Julia Rotow MD @JuliaRotow

a month ago

Join me on August 18 & 19 to hear inspiring stories from Dana-Farber patients and donate to strike out cancer: jimmyfund.gives/guest #KCANCER @TheJimmyFund Sharing progress in personalized treatment for #lungcancer @DFarberThoracic @DFEGFRcenter

0 3 18 1K 0

Julia Rotow MD @JuliaRotow

4 months ago

Follow us at the DFCI EGFR Center for updates on emerging data from #ASCO25 @DFEGFRcenter #NSCLC #EGFR OptiTROP-Lung03: sac-TMT NeoADAURA: neoadj osi/chemo HERTHENA-Lung02: HER3-DXd vs doublet Temab-A MET ADC SACHI: osi/savolitinib MET+ Zipalertinib and BAY2927088 EGFR ex20ins+

1 6 18 2K 3

Julia Rotow MD @JuliaRotow

4 months ago

#ASCO25 is here! Join me Monday at 8:30 AM at the Arie Crown Theater to explore the role of plasma-guided adaptive first-line chemoimmunotherapy for NSCLC, abstract #8515 bit.ly/3Hc6pXn

0 0 5 794 1

Julia Rotow MD @JuliaRotow

3 years ago

I am excited to announce I will be presenting at PER’s NSCLC satellite symposium during #ASCO22 in Chicago. Join us for dinner at 6:30 pm CT and then an in-depth, expert review of NSCLC treatments and clinical trials. Register now: bit.ly/3rRKJoz #LCSM #NSCLC

0 0 8 0 0

Download Image

Julia Rotow MD @JuliaRotow

4 years ago

Kicking off #TTLC22 with a discussion of EGFR-mutant NSCLC. Great to see and discuss all the advances in the last year.

0 0 12 0 0

Download Image

Julia Rotow MD @JuliaRotow

4 years ago

A9 We are on the way to making #lungcancer a chronic disease - seeing gains in long-term survivability and more advances to come #AskReuters #ASCO2021

0 2 7 0 0

Julia Rotow MD @JuliaRotow

4 years ago

A8 @DeboraBruno (abstract 9005 #ASCO21) describes lower rates of NGS testing and clinical trial enrollment among African American versus Caucasian patients, highlighting reduced access to many of the advances that we celebrate at the annual meeting #AskReuters

0 0 4 0 0

Julia Rotow MD @JuliaRotow

4 years ago

A7 Progress at ASCO is always inspiring. Advances in targeted therapies, immunotherapies, and early diagnosis have helped to improve 5-year survival rates for NSCLC, up by 13% in the last five years. #AskReuters #ASCO2021

0 1 4 0 0

Julia Rotow MD @JuliaRotow

4 years ago

A6 Progress in #EGFR exon 20ins NSCLC – a subset lacking targeted therapy options until recently. Now FDA approval of amivantamab and emerging data for exon 20 inhibitors like DZD9008, with a response rate of 48% reported by James Yang at #ASCO2021 (Abstract 9008) #AskReuters

0 2 6 0 0

Julia Rotow MD @JuliaRotow

4 years ago

Exactly this - many gains to be made by effective implementation of existing advances in screening and personalized treatment for all patients. #AskReuters #ASCO2021

Jyoti D Patel @JPatelMD

4 years ago

Exactly this - many gains to be made by effective implementation of existing advances in screening and personalized treatment for all patients. #AskReuters #ASCO2021

0 0 4 0 0

Download Image

0 1 4 0 0

Julia Rotow MD @JuliaRotow

4 years ago

A2 Lung cancer screening reduces risk of dying from lung cancer, so those with a current or former history of tobacco should discuss with their doctors whether screening is right for them. This AHRQ decision aid effectivehealthcare.ahrq.gov/decision-aids/… can help with that discussion #AskReuters